Cargando…
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
Adenoviruses are excellent immunotherapeutic agents with a unique ability to prime and boost immune responses. Recombinant adenoviruses cause immunogenic cancer cell death and subsequent release of tumor antigens for antigen presenting cells, resulting in the priming of potent tumor-specific immunit...
Autores principales: | Vassilev, L, Ranki, T, Joensuu, T, Jäger, E, Karbach, J, Wahle, C, Partanen, K, Kairemo, K, Alanko, T, Turkki, R, Linder, N, Lundin, J, Ristimäki, A, Kankainen, M, Hemminki, A, Backman, C, Dienel, K, von Euler, M, Haavisto, E, Hakonen, T, Juhila, J, Jäderberg, M, Priha, P, Vuolanto, A, Pesonen, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485730/ https://www.ncbi.nlm.nih.gov/pubmed/26140248 http://dx.doi.org/10.1080/2162402X.2015.1017702 |
Ejemplares similares
-
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization
por: Ranki, Tuuli, et al.
Publicado: (2014) -
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
por: Ranki, Tuuli, et al.
Publicado: (2016) -
Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients
por: Majumder, Mamun, et al.
Publicado: (2014) -
Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival
por: Pesonen, Sari, et al.
Publicado: (2015) -
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment
por: Kuryk, Lukasz, et al.
Publicado: (2017)